Stonegate Investment Group LLC Invests $329,000 in Guardant Health, Inc. (NASDAQ:GH)

Stonegate Investment Group LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GHGet Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,292 shares of the company’s stock, valued at approximately $329,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Morgan Stanley raised its stake in shares of Guardant Health by 31.0% during the 3rd quarter. Morgan Stanley now owns 5,560,641 shares of the company’s stock worth $695,134,000 after buying an additional 1,315,317 shares in the last quarter. BlackRock Inc. increased its stake in Guardant Health by 0.5% in the 3rd quarter. BlackRock Inc. now owns 5,555,998 shares of the company’s stock valued at $694,554,000 after purchasing an additional 30,319 shares in the last quarter. Capital Research Global Investors increased its stake in Guardant Health by 144.9% in the 3rd quarter. Capital Research Global Investors now owns 5,286,792 shares of the company’s stock valued at $660,902,000 after purchasing an additional 3,128,063 shares in the last quarter. Viking Global Investors LP increased its stake in Guardant Health by 15.0% in the 3rd quarter. Viking Global Investors LP now owns 4,894,936 shares of the company’s stock valued at $611,916,000 after purchasing an additional 638,573 shares in the last quarter. Finally, Coatue Management LLC increased its stake in Guardant Health by 5.4% in the 3rd quarter. Coatue Management LLC now owns 2,805,273 shares of the company’s stock valued at $350,687,000 after purchasing an additional 144,070 shares in the last quarter. 93.69% of the stock is currently owned by institutional investors.

In other Guardant Health news, Director Stanley J. Meresman sold 4,934 shares of Guardant Health stock in a transaction dated Thursday, March 10th. The stock was sold at an average price of $58.74, for a total value of $289,823.16. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 5.80% of the company’s stock.

GH stock traded down $0.49 during mid-day trading on Wednesday, reaching $33.98. The company had a trading volume of 10,212 shares, compared to its average volume of 1,843,843. The company has a quick ratio of 4.71, a current ratio of 4.87 and a debt-to-equity ratio of 2.13. The stock has a market capitalization of $3.46 billion, a P/E ratio of -8.37 and a beta of 0.70. Guardant Health, Inc. has a one year low of $27.65 and a one year high of $133.82. The stock’s 50-day simple moving average is $59.26 and its two-hundred day simple moving average is $76.72.

Guardant Health (NASDAQ:GHGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($1.21) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.02. Guardant Health had a negative return on equity of 62.68% and a negative net margin of 107.20%. The firm had revenue of $96.10 million for the quarter, compared to analyst estimates of $95.71 million. During the same period last year, the company earned ($1.06) EPS. The business’s quarterly revenue was up 22.2% compared to the same quarter last year. On average, research analysts forecast that Guardant Health, Inc. will post -4.76 EPS for the current fiscal year.

Several research firms recently weighed in on GH. SVB Leerink dropped their price objective on Guardant Health from $170.00 to $140.00 and set an “outperform” rating for the company in a research note on Thursday, February 24th. Stifel Nicolaus dropped their price target on Guardant Health from $160.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, February 24th. Cowen dropped their price target on Guardant Health from $170.00 to $110.00 and set an “outperform” rating for the company in a research report on Thursday, February 24th. Citigroup dropped their price target on Guardant Health from $120.00 to $100.00 in a research report on Friday, May 6th. Finally, Canaccord Genuity Group dropped their price target on Guardant Health from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Thursday, February 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $136.83.

Guardant Health Company Profile (Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Read More

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHGet Rating).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.